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Thyrotoxicosis — Surgical Management in the Era of
Evidence-based Medicine: Experience in Western India
with 752 Cases
S.K. Bhansali1 and H.B. Chandalia,2 1Department of Surgery and 2Department of Endocrinology, Jaslok Hospital and
Research Centre, Mumbai, India.
The three modalities of treatment of thyrotoxicosis, antithyroid therapy (ATT), radio-iodine (I131)
therapy and surgery are not cause-specific. In this paper, we describe our evolving experience with 752
thyrotoxic patients who underwent surgery during the last 40 years and discuss the current scenario
with evidence-based data and observations wherever possible. Thyroidectomy was performed in 428
patients with Grave’s disease (GD), 299 patients with toxic multinodular goitre, and 25 with toxic
solitary nodules (TSN). Whereas 289 patients with GD had surgery for failed ATT, the other 139 had
primary surgery for controversial or debatable indications such as poor socio-economic status, desire
for early pregnancy, poor drug compliance and severe ophthalmopathy. Preoperatively, all patients
were administered carbimazole or propylthiouracil. Non-selective β-blocker propranolol and Lugol’s
iodine were routinely given. In the 25 patients with TSN, hemithyroidectomy was performed. In all
others, subtotal thyroidectomy (STT), was performed leaving behind 4 to 8 g of thyroid tissue: a larger
amount was left behind in those with higher antithyroid antibody titres. During the last decade,
80 patients received near total thyroidectomy (NTT), mainly to minimize recurrence of thyrotoxicosis
and to ameliorate severe eye signs. Because of our increasing experience, no significant increase
in postoperative morbidity was encountered with NTT compared to STT. Transient hoarseness
was observed in 53 patients with STT and only in two patients with NTT. Three patients with STT and
one with NTT developed permanent hoarseness due to recurrent laryngeal nerve palsy; voice in
these four was normalized by intraglottic injection of Teflon paste 6 months after the operation. In
patients undergoing STT, transient hypoparathyroidism was encountered in 63, and permanent
hypoparathyroidism in five. The corresponding figures for NTT were 12 and one, respectively. Of the
500 patients monitoned for 1 year or more, hypothyroidism was observed in 135 and recurrent
thyrotoxicosis in nine. In the same group of 500, exophthalmos was ameliorated in 130 of the 265 with
positive eye signs. Nineteen glands exhibited features of severe Hashitoxicosis with marked destruction
of acini and considerable lymphoid aggregates and follicles. Carcinoma was observed in three other
thyroid glands. (Asian J Surg 2002;25(4):291–9)
INTRODUCTION
Thyrotoxicosis is a clinical syndrome, the hallmark of
which is accelerated metabolism. It is due to a group of
diseases, the common ones being Grave’s disease (GD),
toxic multinodular goitre (TMNG) and toxic solitary
nodule (TSN). An autoimmune disorder, as yet ill-defined,
is a common denominator of all these. The treatment of
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these patients, which aims to lower their thyroid hormone
levels to normal, is, so far, not cause specific. None of the
three modalities of treatment, including antithyroid drugs,
radiotherapy with I131 or surgery, achieve a predictable
and permanent euthyroid status. In this paper, we describe
and discuss our evolving experience of surgery with 752
thyrotoxic patients in Mumbai (Bombay), Western India,
and discuss current trends in the management of these
patients.
PATIENTS AND METHODS
Seven hundred and fifty-two patients who had suffered
from thyrotoxicosis and underwent treatment during the
period of September 1962 to August 2001 were studied.
For comparison and discussion of results, the patients
were divided into two groups according to the period of
treatment: the first group was treated during 1962–1981,
and the second group, during1982–2001. Various aspects
of data are described. Wherever required, data have been
analyzed by calculating the “Standard Error of Difference
(SED)” between the two groups.
Demographic data
Patients with GD (with or without thyromegaly)
outnumbered those with toxic nodular goitre (Table 1).
There was a preponderance of young patients in the third,
fourth and fifth decades of life, with a female to male ratio
of approximately 5:1. Eleven patients were pregnant at
the time of presentation.
Of the 428 patients with GD, 250 had exophthalmos
and/or other occular signs, whereas only 71 of the 324
with nodular goitre had ophthalmopathy. Three patients
had unilateral proptosis and two had asymmetrical
bilateral protrusion of the eye balls.
Twenty-three patients had significant cardiac problems,
of which 14 had atrial fibrillation. Seven patients suffered
from bronchial asthma. Six patients were undergoing
psychiatric treatment. Raised antithyroglobulin or
antimicrosomal antibody titres were observed in 122 of
the 200 patients for whom these were determined.
MODALITY OF INITIAL THERAPY
The following factors or criteria influenced initial
therapy:
(a) age;
(b) reproductive status and potential (including, the pres-
ence or absence of pregnancy, and the desire for early
pregnancy);
(c) morphology of the thyroid gland;
(d) severity of thyrotoxicosis;
(e) displacement and/or compression of the trachea, if
any, and a possible dry cough due to tracheal irritation;
(f) mediastinal extension, if any (especially in those with
polynodular goitre);
(g) cardiac and other medical problems;
(h) degree of ophthalmopathy;
(i) socioeconomic status, especially given the costly
antithyroid drug therapy with a potential of 40% to
50% recurrence;
Table 1. Age and goitre by morphology in 752 patients
Morphology
Age (years) Grave’s disease Nodular goitre Total
No significant goitre Diffuse goitre Multinodular goitre Solitary nodule
10–19 1 22 27 1 51
20–29 3 101 49 1 154
30–39 8 123 121 7 259
40–49 13 106 50 7 176
50–59 8 35 26 7 76
60–69 1 6 21 1 29
≥ 70 0 1 5 1 7
Total 34 394 299 25 752
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(j) psychological make-up;
(k) predicted compliance to treatment; and
(l) patient’s preference to any particular modality of
therapy.
Surgery as the initial treatment was performed in 454
patients, as follows:
(1) 299 patients with TMNG;
(2) 25 patients with TSN (elderly patients with a solitary
nodule, and without tracheal displacement and/or
compression and without cosmetic disfigurement were
treated with I131 after carcinoma was excluded by fine
needle aspiration cytology);
(3) 139 with GD in whom one or more of the following
factors were present (many of these are, to an extent,
debatable indications for primary surgery);
(a) desire for early pregnancy (if antithyroid therapy is
the selected modality of therapy, it is continued for
12–18 months and pregnancy should be delayed
for at least 2–3 years from the start of the therapy
to prevent recurrence);
(b) very young children below the age of 15 years;
(c) poor socio-economic status;
(d) severe ophthalmopathy;
(e) cosmetically unacceptable goitre;
(f) pregnancy, especially the first trimester (surgery is
the best expedient in these);
(g) psychological aberration, leading to poor drug
compliance; and
(h) patient’s insistence for surgery.
Surgery as a secondary treatment was performed in
298 patients with GD (of whom 291 had relapsed after
or during antithyroid drug therapy; four were resistant
to these and three were allergic to the thiourea drug
group).
PREOPERATIVE REGIMEN
All patients were administered an antithyroid drug
(carbimazole 10 mg t.i.d. or q.i.d. or propylthiouracil
500 mg t.i.d.). Since 1970, the non-selective β-blocker
propranolol was also administered (for rapid control of
autonomic manifestations). One to two weeks of this
therapy was deemed adequate for patients with mild to
moderate thyrotoxicosis but in those with severe disease,
T3, T4, thyroid stimulating hormore (TSH) and recent  free
thyroxine levels were assessed serially to ensure the
restoration of euthyroid status prior to surgery. Lugol’s
iodine (10 drops per day) was given for 1 week prior to
the operation to all patients to reduce vascularity and
friability of the gland.
INTRAOPERATIVE CONSIDERATIONS
For the uncommon STN, a hemithyroidectomy was
performed. In patients with GD with a solitary nodule
‘cold’ (hypointense) on isotope scan, a subtotal (STT) or
near total thyroidectomy (NTT) was the procedure of
choice. In all patients with GD (with or without
thyromegaly) and in all patients with TMNG, STT was
performed, leaving behind a remnant of about 4–8 g of
thyroid tissue. If the patient had a high preoperative titre
of antithyroglobulin/antimicrosomal antibodies, an
additional 2 to 3 g of thyroid tissue was preserved.
However, during the last decade, 80 patients underwent
NTT leaving behind only 1–2 g of thyroid tissue (or the
Dunhill procedure of total lobectomy on one side and
near total lobectomy on the opposite side), as the operation
of choice.
The external laryngeal branch (ELN) of the superior
laryngeal nerve (SLN) was demonstrated (in the majority
of patients) by entering the avascular space of Reeve’s
medial to the upper pole of the gland, which was
then retracted laterally. Ligation and division of the
individual branches of superior thyroid artery and the
corresponding veins further safeguarded the ELN from
damage.
The trunk of the inferior thyroid artery was ligated in
continuity well lateral to the thyroid gland. The recurrent
laryngeal nerve (RLN) was identified in more than 80% of
the cases. The branches of inferior thyroid artery were
then ligated and divided close to the gland. The identified
nerve was followed until its entry into the larynx, without
lifting it from its bed. This entry point was usually within
3 mm of the ligament of Berry.
The dissection of the thyroid gland was kept close
to the glandular capsule to minimize damage to the
parathyroid glands. In the early years, the thyroid
gland was resected after clamping with straight, fine
haemostasis. But during the last 10 years, these clamps
have been substituted with pre-resection haemostatic
sutures of an absorbable material. One of the parathyroid
glands was excised accidentally in 11 patients. The
glands were sliced into eight to 10 parts, which
were implanted into the sternomastoid muscle (after
histological verification on a frozen section of one of
the slices).
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POSTOPERATIVE MANAGEMENT
Serum calcium levels were determined 2, 5 and 15
days and 3 months after surgery; the schedule was
modified if a patient exhibited hypoparathyroidism. T3,
T4 and TSH were determined 2 months, 6 months and
1 year after surgery unless the patient developed hy-
pothyroidism earlier than this time frame.
The three patients requiring semi-emergency surgery
were administered corticosteroids, β-blockers and Lugol’s
iodine postoperatively to prevent thyroid storm.
RESULTS
There was no mortality in the series. Two patients
developed postoperative thyroid crises, which were
successfully treated with β-blockers, steroids, iodine and
intravenous glucose. One patient with a progressive neck
haematoma required re-exploration. For comparison,
the patients were divided into two groups, one group
treated during 1962–1981 and the other during 1982–
2001. Tables 2 and 3 summarize recurrent nerve paresis
and hypoparathyroidism, both transient and permanent,
in relation to to the type of thyroidectomy (hemithy-
roidectomy, STT and NTT) and to the period of treatment.
Transient RLN paresis recovered completely in 4 to
16 weeks. In three of the four patients with permanent
unilateral RLN palsy, the quality of voice was normalized
by intraglottic injection of Teflon paste (Ethicon,
Edinburgh, Scotland) 4 to 6 months after surgery (waiting
for at least 4 months was deemed mandatory, as recovery
from neuropraxia usually occurs by the fourth month).
Two patients had mild, but permanent, voice change
without RLN palsy. This voice change may have been
Table 2. Recurrent nerve palsy
Recurrent nerve palsy (no. of cases)
Break-up by period
                           Total no. of cases 1962–1981 1982–2001                      Total
Operation 1962–1981 1982–2001 Transient Permanent Transient Permanent Transient Permanent
HT 14 11 0 0 0 0 0 0
STT 380 267   31*    2**  22*    1** 53 3
NTT 0 80 – – 2 1 2 1
Total 394 358 31 1 24 2 55 4
* SED 2.19 (not significant). ** SED 0.51 (not significant). HT = hemithyroidectomy; STT = subtotal thyroidectomy; NTT = near
total thyroidectomy.
Table 3. Hypoparathyroidism
Hypoparathyroidism (no. of cases)
Break-up by period
                          Total no. of cases 1962–1981 1982–2001                      Total
Operation 1962–1981 1982–2001 Transient Permanent Transient Permanent Transient Permanent
HT 14 11 0 0 0 0 0 0
STT 380 267   35*    3**   28*    2** 63 5
NTT 0 80 – – 12 1 12 1
Total 394 358 35 3 40 3 75 6
*SED 2.39 (not significant). **SED 0.69 (not significant). HT = hemithyroidectomy; STT = subtotal thyroidectomy; NTT = near–
total thyroidectomy.
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due to damage of the external laryngeal branch of
the SLN.
Calcium deficiency (temporary as well as permanent)
was controlled by oral calcium and vitamin D3
(supplemented initially by intravenous calcium gluconate).
In many patients, carefully monitored vitamin  D3 injection
(6 lac units) minimized the initial oral calcium doses.
Five hundred patients were monitored for 6 months to
20 years. Hypothyroidism (manifesting after 1 to 3 months
and mostly within 6 to 12 months, postoperatively) was
observed in 135 patients (of whom 38 had undergone
NTT). Hypothyroidism was well controlled with levo-
thyroxine. Nine patients (all of whom had undergone STT)
developed recurrent hyperthyroidism; four were
reoperated upon and five received an ablative dose of I131.
Of the 80 patients who had undergone STT, 38 developed
postoperative hypothyroidism but none developed
recurrent thyrotoxicosis. The NTT enhanced chances of
postoperative hypothyroidism but considerably reduced
the possibility of recurrence of hyperthyroidism.
Of the 500 patients, 265 had ophthalmopathy prior
to treatment (Table 4). Exophthalmos decreased in 130
patients and remained unchanged in 134 patients. A single
patient who developed malignant exophthalmos needed
Nafzigger’s orbital roof decompression to save the eyeball.
Steroids were administered to 22 patients with persistent
ophthalmopathy; mild improvement was observed in 18,
while there was no improvement in four patients.
THYROID HISTOLOGY
The characteristic histological changes of an overactive
but treated gland were observed. Thus, hyperplasia of
cells, with multilayered acini, and a variable admixture
of colloid hyperinvolution, were evident. Excessive lym-
phoid aggregates and/or follicles were found in the
thyroid glands of about 20% of the patients. Considerable
destruction of the acini with marked lymphoid aggregates
and follicles (Hashitoxicosis) was reported in 19 glands.
Three patients had carcinoma: papillary carcinoma in
one with GD; follicular carcinoma in one with TMNG
and in one with TSN.
DISCUSSION
The clinical syndrome of thyrotoxicosis can be caused
by many diseases, the two most common causes being
GD and toxic nodular goitre. GD is an organ-specific
autoimmune disorder caused by antibodies to the TSH
receptors that are stimulatory in nature.1 The role of
autoimmunity in TMNG has yet to be elucidated. Kraiem
et al found thyroid-stimulating auto-immunoglobulin in
42% of patients with TMNG.2 Patients with solitary nodules
may have a hyperfunctioning or a cold solitary nodule in
Grave’s thyroid gland (the latter having a significantly
higher malignant potential).
The relative frequency of GD vis-à-vis TMNG varies
from series to series. In Japan, TMNG is rare and GD
constitutes the bulk of cases of thyrotoxicosis,3 whereas
in most surgical series from the USA and other countries,
GD constitutes approximately two-thirds of cases. In our
surgical series (current and past), toxic nodular goitre
constituted almost 45% of the cases.4–6 Mishra7 from
Lucknow, India and Dorairajan8 from Chennai, India,
both report a preponderance of GD.
The three available modalities of therapy include
thionamides, radioactive iodine ablation and surgery. It
is not within the scope of this discussion to analyze each




Cause of thyrotoxicosis Total (no.) Ophthalmopathy Total Ophthalmopathy Ophthalmopathy
(no.) (no.) improved after surgery
Grave’s disease 428 250 284 213 101
Toxic multinodular goitre 299 71 201 52 29
Toxic solitary nodule 25 0 15 – –
Total 752 321 500 265 130
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Indications for surgery
Surgery may be carried out either as primary treat-
ment or as secondary therapy after failure of other modes
of management.
Surgery as primary treatment
The indications are:
(a) TMNG;
(b) Solitary hyperfunctioning (toxic) nodule with
thyrotoxicosis, especially in the young, or when there
is tracheal compression or cosmetic disfigurement.
Percutaneous ethanol injection therapy is being evalu-
ated by Freitas;9
(c) A patient with GD with one or more of the following
features/factors (these indications may be debatable):
(i) Cold solitary nodule, as chances of malignancy
in this are high10,11 (though neither hyperthy-
roidism per se nor I131 therapy increases risk of
cancer);




(v) Desire for early pregnancy (as it is advisable to
avoid pregnancy for at least 2 years after starting
thyrostatic drugs);
(vi) Poor socio-economic status (antithyroid drugs
are expensive, treatment must be continued for
at least 18 months and chances of recurrence are
30%–45%);14–17
(vii) Patients with severe exophthalmos;18 and
(viii) Likelihood of poor compliance because of psy-
chiatric aberrations.
Patients with considerable tracheal compression or
tracheal deviation require semi-emergency surgery.
Surgery as secondary treatment
Surgery as a secondary treatment is required for patients
with GD who relapse on/after thiourea administration
(or the rare ones who exhibit drug allergy or resistance).
Recurrence is rare after prudently administered
radioiodine.17 Antithyroid drugs, as well as I131 ablation,
should be avoided in patients with severe ophthalmopathy,
as eye problems deteriorate in a significant number of
such patients.16,18 Frilling et al utilized an accurate
ophthalmopathy scoring system, and advocated surgery
in those patients with GD who have severe ophthalmo-
pathy, as a means of ameliorating eye problems.18 They
found an improvement in about 70% of their cases.
A solitary nodule successfully treated by I131 becomes
non-functional on the isotope scan by about 6 months
after treatment, whereas those with limited response will
retain some functional activity.19 Hence, if after I131
therapy the solitary nodule exhibits activity on the iso-
tope scan, it should be excised.
Semi-emergency surgery
Semi-emergency surgery may be required for patients
with severe tracheal compression/displacement.20 Early
surgery is also recommended for those with severe
physiological compromise (and those with amiodarone-
induced thyrotoxicosis) who do not respond to conserva-
tive management.21
Preoperative treatment
Preoperatively, the thyroid function should be nor-
malized by administration of thyrostatic drugs; otherwise,
there is a risk of postoperative thyroid storm.
Propylthiouracil is the ideal drug for pharmacological
preparation, as it not only inhibits synthesis of thyroid
hormones, but also reduces the rate of peripheral conver-
sion of T4 to T3, unlike carbimazole, or its active meta-
bolite, methimazole.22 In India, the cost factor and lack
of readily available propylthiouracil often forces us
to use carbimazole. β-Blockers administered simultane-
ously with antithyroid drugs quickly control hyper-
sympathethomimetic manifestations. Bronchospasm and
gross left ventricular dysfunction contraindicate use of
β-blockers. If β-blockade is decided upon, non-selective
propranolol is preferred, as it also reduces elevated
oxygen consumption by 50%,23 and also inhibits
peripheral conversion of T4 to T3.
We routinely administer Lugol’s iodine preoperatively
for 1 week. Chang et al, by studying blood volume flow
with the help of pulsed Doppler ultrasonography,24 Burns,
by resistance index studies25 and Woodcock and
colleagues, by using duplex scanning of the thyroid,26
demonstrated normalization of blood flow in toxic goitre
by administration of Lugol’s solution. The decrease in
thyroid gland vascularity and friability limits intraoperative
bleeding and related problems.25
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In patients requiring semi-emergency surgery, steroids
are administered pre-, intra- and postoperatively, in
addition to the therapeutic measures outlined above, to
minimize chances of postoperative thyroid crisis. Recently,
Mercado demonstrated that therapy with cholestyramine
in these patients achieves a rapid decline in thyroid
hormone level by diminishing the increased enterohepatic
circulation of thyroid hormones.27 Hence, this drug, too,
may be a useful adjuvant in semi-emergency situations.
Intraoperative considerations
Intraoperative steps to safeguard the recurrent and
external laryngeal branch of the SLNs and parathyroid
glands have been outlined already in the initial part of
this report. Reeve’s manoeuvre of lateralization of
the superior pole of the thyroid gland followed by ligation
of the superior thyroid vessels safeguards the ELN.28
Routine identification of the RLN greatly decreases the
incidence of nerve injury,29 but is possible in less than
85% of cases.30 Mono-lateral vocal cord hypomotility is
deemed permanent if it lasts beyond 3–4 months: after
this interval, the quality of voice can be restored to near
normality by injection of Teflon paste into the glottic
region via a laryngoscope. Temporary hoarseness of
voice occurs in about 5% to 10% of cases and permanent
hoarseness, in 0.5% to 1%.31,32
Ligation of the trunk of inferior thyroid artery (ITA)
remains controversial. The advantage of initial trunk
ligation is that it produces a relatively bloodless field.
Some surgeons postulate that ligation of the trunk of ITA
causes hypocalcaemia by devascularization of parathy-
roid gland; they advocate ligation of only the branches of
the ITA near the thyroid capsule, thus, preserving the
blood supply to parathyroid glands.32 Nonetheless, this
view is not shared by others 33–35 including the current
author. Apart from ligation of the ITA, there are other
possible factors leading to hypocalcaemia, such as
the inadvertent excision of a parathyroid gland, infarction
of the gland, autoimmune disorders and severe
thyrotoxicosis.36 An inadvertently excised parathyroid
gland is best transplanted into the sternomastoid muscle37
after slicing (and confirming the presence of the gland on
frozen section histopathology), with a reported successful
function at upwards of 75%.38,39 This precaution reduces
the incidence of permanent postoperative hypocalcaemia.
The high incidence (> 20%) of post-thyroidectomy
temporary hypocalcaemia is not related to the truncal
ligation of the ITA.40 Probably, the small end arteries from
the trachea and oesophagus provide perfusion of the
parathyroid glands. Also neo-anastomotic branches
between the parathyroid arteries and the thyroid remnant
may also be effective in perfusion of parathyroid
glands.41 The incidence of permanent hypocalcaemia
ranges from 2% to 5%.42
Extent of resection
Until about a decade ago, the extent of resection
performed was STT leaving behind 4–8 g of thyroid
tissue. However, with STT, recurrent thyrotoxicosis
develops in 5% to 10% of patients.43–45 As a result, over
the last decade, the trend is for NTT or total thyroidectomy
(TT).46 Recurrence is especially more frequently encoun-
tered in the very young patients with severe thyrotoxicosis,
and those with normal levels of antithyroid antibodies.
Also, exophthalmos does not regress as well after STT as
after NTT/TT.18
Revision surgery (either TT or NTT) for recurrent
thyrotoxicosis is associated with a higher morbidity than
ab initio TT/NTTT.47 Per contra ab initio TT/NTT is not
associated with a higher morbidity than that associated
with STT,32,42 provided TT (or NTT) is performed by an
experienced “high volume thyroid surgeon”.48 The
Maryland cross-sectional survey of 5,860 thyroidectomies
after adjustment for case mix (age, race,co-morbidities,
diagnosis, procedures, etc.) and hospital volume, showed
that “highest volume thyroid surgeons” had the lowest
complication rates for TT. Our analysis of the operation
in two groups of two decades each does not show
increased morbidity with NTT. A recent mail survey of
75 endocrine surgeons in Australia and New Zealand
revealed that 60% of the surgeons perform TT, with
decreased incidence of recurrent thyrotoxicosis, and a
reduction in the need for revision thyroidectomy.46
STT with video-surgical techniques and the use of
an ultrasound-activated scalpel (or shear) as a cutting-
cum-coagulation device has been reported by Yamamoto
and colleagues.49
Postoperative complications
Surgical mortality is practically nil. The fatalities are
usually due to associated cardiac and other co-morbidities.
The issue of recurrent thyrotoxicosis has already been
discussed. Whilst transient hypothyroidism is frequently
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seen (possibly due to temporary devascularization of the
thyroid remnant), the incidence of permanent
hypothyroidism varies, from 5% to 40% with STT43,44,50
With NTT, it is necessarily higher. Apart from the extent
of surgery,50,51 other factors that influence the incidence
of postoperative hypothyroidism are: (a) preoperative
levels of antithyroglobulin and antimicrosomal antibodies,
and  (b) the extent of lymphocytic infiltration observed
histologically.52,53 Recently, Shimizu and colleagues54
have reported successful auto-transplantation (in forearm
muscles) of cryopreserved thyroid tissue (obtained at
thyroidectomy) to counter postoperative hypothyroidism;
the auto-transplantation was carried out 18 months or
more after the initial surgery. It is possible that this
technique (or its refinement or modification, if need be)
may benefit some patients with post-thyroidectomy
hypothyroidism.
Associated carcinoma
The incidence of carcinoma in TMNG and GD has
been reported at around 1–7%.7,45,55 A solitary nodule
developing in Grave’s thyroid, cold on isotope scan
and echogenic on ultrasound, has a higher risk of
malignancy.11
Eye changes
Eye changes will generally ameliorate or remain static
with the control of hyperthyroidism; but, on occasion,
ophthalmopathy will progress despite thyroid ablation.
Generally, patients with severe ophthalmopathy benefit
more from surgical TT or NTT.16 The lack of predictable
effects of treatment on ophthalmopathy suggests that the
thyrotoxicosis and ophthalmopathy in GD are, perhaps,
two distinct auto-immune phenomena with a high degree
of concurrence.
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